Direct-to-consumer skin-care brand BioClarity has raised a $13 million funding round, led by Prolog Ventures.
Prolog, a health and wellness firm, invested $6 million to lead the round, and was joined by the company’s other existing investors.
BioClarity launched in 2016 with a three-step regimen meant to treat acne. The group’s product lineup has since expanded to include an eye cream, clarifying and hydrating masks and serum. Prices range from $9.95 for cleanser to $32.95 for vegan supplements. The brand’s business is growing, according to Rick Sliter, president and chief executive officer.
BioClarity centers around Floralux, a proprietary ingredient that the company claims has a synergistic effect when combined with botanics and salicylic acid, and can be used to treat breakouts without dryness or itchiness. The company referred to the chlorophyll-based ingredient as a “detoxifier” in an interview with WWD in 2017. BioClarity products are vegan, cruelty-free and made without parabens, sulfates and phthalates.
“Personal care is a key area of focus for Prolog…[BioClarity’s] promise is rare and powerful — you can have skin-care products featuring a unique patented ingredient that is clinically validated to work well, and yet is also plant-based, gentle and reasonably priced. We believe this makes BioClarity well positioned for the needs and lifestyle of Millennial and Gen Z consumers,” said Prolog partner Rob Rosenberg.
For more from WWD.com, see: